Logo Logo
Switch Language to German
Schunk, Michaela; Le, Lien; Syunyaeva, Zulfiya; Haberland, Birgit; Tänzler, Susanne; Mansmann, Ulrich ORCID: 0000-0002-9955-8906; Schwarzkopf, Larissa; Seidl, Hildegard; Streitwieser, Sabine; Hofmann, Miriam; Müller, Thomas; Weiß, Tobias; Morawietz, Philipp; Rehfuess, Eva Annette; Huber, Rudolf Maria; Berger, Ursula; Bausewein, Claudia ORCID: 0000-0002-0958-3041 (2021): Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany. A pragmatic fast track randomised controlled trial (BreathEase). In: The European Respiratory Journal, Vol. 57, No. 2
Full text not available from 'Open Access LMU'.


Breathlessness is a common and distressing symptom in advanced stages of malignant and non-malignant disease [1–4]. Breathlessness is highly prevalent, occurring in up to 80% of patients with advanced cancer, in around 56–98% of patients with chronic obstructive pulmonary disease (COPD) and in up to 90% of patients with chronic heart failure (CHF) [5, 6]. Patients with chronic breathlessness resulting from advanced disease report high symptom burden, palliative care needs [7–9] and suffer from anxiety and depression [10]. Negative consequences on health and quality of life (QoL) have been shown, e.g. for COPD patients [11]. Breathlessness is one of the most common reasons for emergency department visits and hospital admissions in cancer patients [12–14].